Currently, there are three approved PD-L1 inhibitors by the US Food and Drug Administration (FDA) for cancer treatment ranging from non-small cell lung cancer to Merkel cell carcinoma. The gene discussed is CD274; the disease is non-small cell lung carcinoma.